Altimmune, Inc. (ALT)

Altimmune is transitioning into a late-stage biotechnology company centered on pemvidutide, with programs targeting metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company has begun its pivotal MASH study, completed enrollment in its ALD trial, and reported positive mid-stage AUD results. New board appointments will support development and potential commercialization efforts.